Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing 100049, PR China.
State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, PR China.
Drug Resist Updat. 2024 Jan;72:101018. doi: 10.1016/j.drup.2023.101018. Epub 2023 Nov 11.
Cuproptosis is a newly identified form of cell death driven by copper. Recently, the role of copper and copper triggered cell death in the pathogenesis of cancers have attracted attentions. Cuproptosis has garnered enormous interest in cancer research communities because of its great potential for cancer therapy. Copper-based treatment exerts an inhibiting role in tumor growth and may open the door for the treatment of chemotherapy-insensitive tumors. In this review, we provide a critical analysis on copper homeostasis and the role of copper dysregulation in the development and progression of cancers. Then the core molecular mechanisms of cuproptosis and its role in cancer is discussed, followed by summarizing the current understanding of copper-based agents (copper chelators, copper ionophores, and copper complexes-based dynamic therapy) for cancer treatment. Additionally, we summarize the emerging data on copper complexes-based agents and copper ionophores to subdue tumor chemotherapy resistance in different types of cancers. We also review the small-molecule compounds and nanoparticles (NPs) that may kill cancer cells by inducing cuproptosis, which will shed new light on the development of anticancer drugs through inducing cuproptosis in the future. Finally, the important concepts and pressing questions of cuproptosis in future research that should be focused on were discussed. This review article suggests that targeting cuproptosis could be a novel antitumor therapy and treatment strategy to overcome cancer drug resistance.
铜死亡是一种新发现的由铜驱动的细胞死亡形式。最近,铜和铜引发的细胞死亡在癌症发病机制中的作用引起了人们的关注。铜死亡因其在癌症治疗中的巨大潜力而在癌症研究界引起了广泛关注。基于铜的治疗方法在肿瘤生长中发挥抑制作用,可能为治疗化疗耐药肿瘤开辟道路。在这篇综述中,我们对铜动态平衡和铜失调在癌症发生和进展中的作用进行了批判性分析。然后讨论了铜死亡的核心分子机制及其在癌症中的作用,接着总结了目前对铜基药物(铜螯合剂、铜离子载体和基于铜复合物的动态治疗)治疗癌症的理解。此外,我们总结了基于铜复合物的药物和铜离子载体在不同类型癌症中抑制肿瘤化疗耐药的新数据。我们还回顾了通过诱导铜死亡来杀伤癌细胞的小分子化合物和纳米颗粒(NPs),这将为未来通过诱导铜死亡开发抗癌药物提供新的思路。最后,讨论了铜死亡在未来研究中需要关注的重要概念和紧迫问题。本文综述表明,靶向铜死亡可能是一种新的抗肿瘤治疗方法和治疗策略,以克服癌症药物耐药性。
Drug Resist Updat. 2024-1
J Hematol Oncol. 2024-8-16
Biomed Pharmacother. 2024-7
Mol Cancer. 2023-3-7
Mol Cell Biochem. 2023-12
Biochim Biophys Acta Rev Cancer. 2023-11
Biochim Biophys Acta Rev Cancer. 2024-11
Cell Commun Signal. 2024-5-1
Apoptosis. 2024-10
Apoptosis. 2025-9-9
Mater Today Bio. 2025-7-29
J Inflamm Res. 2025-7-25
Oncol Lett. 2025-7-14